According to the partners, up to 70 percent of pharma pipelines use companion or complementary diagnostics. Under the collaboration, ARUP and Labceutics will provide pharma companies services that allow them to efficiently incorporate such tests in their drug development and commercialization efforts through lab networks.
ARUP provides test development and validation services to pharmaceutical partners through a program called PharmaDx, and is working with a number of drug firms in this regard in a variety of disease areas, including oncology and infectious diseases. According to the firm, its services reach more than 20 percent of US hospital labs.
Labceutics, a division of the personalized medicine-focused consulting firm Diaceutics, provides lab implementation services to pharma. The firm will help drug companies create lab networks to perform companion and complementary tests that are important for the delivery of their drugs, and then work with labs to ensure they are performing the tests efficiently and according to quality standards.
"With our Labceutics partnership, we will be providing specific solutions for the pharmaceutical industry with novel tests that support targeted therapy launches and ongoing clinical testing," Sherrie Perkins, senior VP of R&D at ARUP, said in a statement.